Research & Academia

Executive Summary- ADC clinical development Antibody–drug conjugates (ADCs) have achieved major advances at the scientific and engineering levels, yet clinical success remains highly variable. Many ADCs: show strong performance in preclinical models demonstrate early responses in Phase I trials ultimately fail in Phase II or Phase III studies This indicates that the challenge is not solely molecular design, but rather: ADC clinical development strategy Successful ADC programs

In Vivo CAR-T Autoimmune Therapy: Reprogramming the Immune System In Situ Introduction CAR-T therapy has already transformed hematologic oncology. Yet its expansion into autoimmune disease has been limited by cost, manufacturing complexity, and scalability challenges. A new paradigm is emerging: in vivo CAR-T autoimmune therapy . Instead of extracting T cells, engineering them ex vivo, and reinfusing them weeks later, in vivo approaches program immune cells directly inside th

Executive Summary Over the past decade, antibody–drug conjugates (ADCs) have become one of the most important therapeutic platforms in oncology drug development. Several ADCs have achieved major clinical success, particularly in breast cancer, hematologic malignancies, and emerging solid tumor indications. However, early generations of ADCs were still constrained by important limitations, including: reliance on a single payload mechanism dependence on a single tumor antigen

Introduction Following the success of COVID-19 vaccines, mRNA technology has rapidly emerged as one of the most important platforms in modern biotechnology . By enabling human cells to temporarily produce therapeutic proteins, mRNA therapeutics are being explored across a wide range of medical applications, including: Vaccines Cancer immunotherapy Protein replacement therapies Gene editing (CRISPR delivery) However, mRNA molecules are inherently fragile. Without protection,

Article Positioning This is Series (V) in the ADC deep-dive. In previous articles, we explored: The system-level design of antibody–drug conjugates Linker and conjugation engineering ADC target selection Clinical translation and platform strategy This article focuses on a critical reality: Even clinically successful ADCs eventually face ADC resistance . Understanding the mechanisms of ADC resistance is essential not only for biology, but for long-term product strategy. Execut

Introduction This is the fourth article in the ADC series. If previous articles discussed: The integrated system of antibody–drug conjugates (Series I) The evolution of ADC generations (Series II) Linker and conjugation as the engineering core (Series III) This article moves upstream to a more fundamental question: ADC target selection — which antigens are biologically suitable for ADC development? This article is written for readers without prior ADC experience who want to u

Introduction Why Has the LNP Field Long Lacked a “PDB-Level” Database? If you have worked directly on lipid nanoparticle (LNP) design for mRNA, siRNA, or CRISPR delivery, this situation may feel familiar: Extensive LNP screening has been performed across the field, yet much of the resulting data never truly accumulates into shared knowledge. The LNP field faces a structural challenge: large volumes of data exist, but they are highly fragmented and difficult to integrate. Diff

Introduction This is the third article in LuTra Studio’s ADC series, written for readers without a chemistry or ADC engineering background  who want to understand why many antibody–drug conjugate programs fail despite having strong targets and potent payloads . This article focuses on ADC linker design and conjugation strategy —two elements often treated as technical details, but which frequently become structural failure points  in clinical development and manufacturing scal

This is the second article in LuTra Studio’s ADC series, written for readers without prior ADC expertise who want to understand ADC evolution—specifically, why antibody–drug conjugates experienced widespread failures in the 2000s but emerged as one of the most important oncology platforms after 2020. Rather than starting with definitions, this article traces the historical failures, engineering corrections, and strategic shifts that shaped modern ADC development across differ

Introduction In the journey of cross-disciplinary learning, molecular biology is often the first real wall for anyone without a formal biology background . For those of us trained in engineering, the difficulty is rarely a lack of effort. Instead, it usually comes from three recurring challenges: Too many new terms and relationships appearing all at once Uncertainty about which concepts are essential and which can be temporarily set aside Learning ideas without knowing how th

This long-form article is written for readers without prior ADC expertise who want to understand why antibody–drug conjugates have become one of the most important oncology drug platforms of the 2020s. Starting from first principles, it gradually builds toward engineering trade-offs and industry strategy. Executive Summary Antibody–drug conjugates (ADCs) are designed to deliver extremely potent drugs directly into cancer cells using antibodies as targeting vehicles. ADC suc

Introduction: Why Cancer Vaccines Are Back in Focus For decades, the concept of a cancer vaccine occupied an uncertain space in oncology. Early therapeutic cancer vaccine efforts frequently failed to demonstrate meaningful clinical benefit, leading to skepticism about whether the immune system could be reliably trained to recognize and eliminate tumors (1). This perception has shifted dramatically in recent years. Advances in tumor genomics, neoantigen discovery, and RNA del

Introduction In the world of mRNA therapeutics and lipid nanoparticles (LNPs), PEG-lipids have long been treated as a default design choice . They are used to: Provide steric shielding to prevent aggregation Extend circulation time Reduce nonspecific interactions However, as mRNA technologies move beyond one-time vaccines toward repeat-dose systemic therapies , PEG-associated risks—most notably anti-PEG antibodies and the accelerated blood clearance (ABC) phenomenon —are bec

Introduction: The Next Bottleneck for LNPs Is Not Encapsulation — It’s Precision Lipid nanoparticles (LNPs) have proven their value by enabling the clinical success of mRNA vaccines and multiple nucleic acid therapeutics. However, as therapeutic targets expand beyond the liver to immune cells, the central nervous system, and solid tumors, non-specific biodistribution has emerged as a primary limitation of current LNP platforms . For many LNP-based systems, the key challenge i

Introduction Many engineers share the same anxiety If you come from an engineering background and are exploring biomedicine or life sciences, you may have asked yourself similar questions: Will I ever be “biological” enough? Is my engineering training holding me back? What should I keep, and what should I unlearn? These concerns are common—and valid. Three hidden advantages of an engineering background Through my own transition from engineering into biomedicine and bioinforma

Cross-Disciplinary Learning Is Not Talent: How I Self-Learned My Way from Engineering to Biomedicine and Bioinformatics I didn’t start on the “right” path My academic training began in engineering—chemical engineering and civil engineering. At the time, biology felt distant and abstract. Molecular mechanisms, cellular signaling, and biological data analysis were not part of my formal education. What engineering gave me was not certainty, but a habit of structured thinking: br

Introduction If you are reading this article, congratulations. It likely means you have: completed your applications , written your SOPs and CVs , waited through months of uncertainty, and finally received one or more U.S. graduate school offers . At this stage, many applicants realize something unexpected: Applying was hard—but choosing is often harder. To compare U.S. graduate school offers can be more stressful than the application process itself. This article is meant to

Introduction In U.S. graduate school applications, the Curriculum Vitae (CV) often plays the most important role during the initial screening stage. However, once applications move into deeper review, the document that truly differentiates candidates is the: U.S. graduate school SOP (Statement of Purpose). Because the SOP and cover letter share very similar structure and logic , this article discusses them together and provides a unified framework you can apply to both. If y

Introduction Following the previous articles on application documents (SOP) , school selection , and emailing professors , this article focuses on another critical—but often underestimated—component of U.S. graduate school applications: The U.S. graduate school CV (Curriculum Vitae). Typical U.S. graduate school applications may include: Statement of Purpose (SOP) Curriculum Vitae (CV) (For some programs) Diversity Statement (For some programs) Research Interest or Personal S

Introduction In the previous articles, I discussed how to prepare application documents (SOP and CV) and how to choose a U.S. graduate school . In this article, I focus on one of the most frequently asked—and misunderstood—questions: How should you email professors for U.S. graduate school applications? Whether you are applying for a master’s program, a PhD, or a postdoctoral position, emailing professors for U.S. graduate school is often your first direct academic interacti